Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.70 |
| ▸ | PLAU | P00749 | 8/20 | 0.69 |
| ▸ | F2 | P00734 | 7/20 | 0.69 |
| ▸ | PLAT | P00750 | 7/20 | 0.69 |
| ▸ | PLG | P00747 | 7/20 | 0.64 |
| ▸ | KLK8 | O60259 | 5/20 | 0.64 |
| ▸ | KLK4 | Q9Y5K2 | 5/20 | 0.64 |
| ▸ | KLK1 | P06870 | 4/20 | 0.64 |
| ▸ | F10 | P00742 | 4/20 | 0.63 |
| ▸ | KLK2 | P20151 | 3/20 | 0.63 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403534 | 0.88 | F2 (0.86) | ELANEPLAUF2PLATPLG | |
| SCHEMBL5689257 | 0.84 | ELANE (0.77) | ELANEPLAUF2PLATPLG | |
| SCHEMBL15397886 | 0.84 | ACE2 (0.56) | ELANEPLAUF2PLATPRTN3 | |
| SCHEMBL9971041 | 0.83 | PLAU (0.75) | ELANEPLAUF2PLATPLG | |
| SCHEMBL9856806 | 0.82 | F2 (0.70) | ELANEPLAUF2PLATPLG | |
| SCHEMBL2249441 | 0.82 | PLAU (1.00) | ELANEPLAUF2PLATPLG | |
| SCHEMBL9970972 | 0.82 | ELANE (1.00) | ELANEPLAUF2PLATPLG | |
| SCHEMBL7397171 | 0.80 | F2 (0.69) | ELANEPLAUF2PLATPLG | |
| SCHEMBL1436662 | 0.80 | ELANE (0.66) | ELANEPLAUF2PLATPLG | |
| SCHEMBL12354625 | 0.79 | F2 (0.75) | ELANEPLAUF2PLATPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063743-A1 | Peptide deformylase activated prodrugs | BALLATORE CARLO | 2006-03-23 | — | — | US | disclosed |
| US-7001922-B2 | Peptide deformylase activated prodrugs | CELMED ONCOLOGY (USA), INC. (CA) | 2006-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063743-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | ELANE 1467/4885PLAU 540/4885F2 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.